The Gilead Sciences Acquisition of Arcellx reached its successful conclusion today, marking a transformative milestone for the biopharmaceutical giant’s oncology division. By folding Arcellx into its wholly-owned subsidiary, Kite, Gilead has secured full global rights to anitocabtagene autoleucel (anito-cel), a next-generation CAR T-cell therapy currently under FDA review for the treatment of relapsed or refractory multiple myeloma.
Strategic Value of the Gilead Sciences Acquisition of Arcellx
This $7.8 billion transaction reflects Gilead’s commitment to becoming a leader in cell therapy. Under the terms of the deal, Gilead paid $115.00 per share in cash, plus a contingent value right (CVR) of $5.00 per share, which is tied to achieving $6 billion in cumulative net sales by 2029.
By bringing the Gilead Sciences Acquisition of Arcellx to a close, the company eliminates future profit-sharing and royalty obligations previously established under their 2022 collaboration agreement. This move is expected to be accretive to earnings per share starting in 2028, following the anticipated 2026 market entry.
Clinical Excellence: Data from the iMMagine-1 Trial
A primary driver for the Gilead Sciences Acquisition of Arcellx was the exceptional clinical data presented at recent medical congresses, including the American Society of Hematology (ASH) Annual Meeting. The pivotal Phase 2 iMMagine-1 study demonstrated that anito-cel offers not only deep responses but also a safety profile that distinguishes it from existing BCMA-directed therapies.
Learn More: Gilead Acquire Tubulis in Landmark $5 Billion ADC Strategic Expansion
Efficacy Results for Anito-cel (iMMagine-1 Trial)
| Metric | Result (n=117) |
| Overall Response Rate (ORR) | 96% |
| Complete Response (sCR/CR) | 74% |
| MRD Negativity Rate (10⁻⁵) | 95% |
| 12-Month Progression-Free Survival | 82.1% |
| 12-Month Overall Survival | 94.0% |
AstraZeneca Q3 2026 Results: Total Revenue Rises 7% to $46.9bn as Oncology Leads Growth and FY2026 Guidance Holds
AstraZeneca Q3 2026 results, published 30 October 2026, show nine-month revenue of $46.9bn, up 7% at CER, and Core EPS of $8.00, up 14%. Oncology […]
AbbVie Q3 2026 Results: Skyrizi, Rinvoq and Vraylar Drive $17.404 Billion Revenue as EPS Guidance Rises
AbbVie Q3 2026 Results show $17.404B revenue, led by Skyrizi and Rinvoq, with higher 2026 EPS guidance and a 5.2% dividend increase. […]
Merck Daejeon Bioprocessing Center Opens With €300 Million Investment to Expand Asia-Pacific Biologics Supply
The Merck Daejeon bioprocessing center opened on 29 October 2026 with a €300 million-plus investment, adding cell culture media, process liquids and sterile sampling capacity […]
The Road to Commercialization in 2026
With the FDA having accepted the Biologics License Application (BLA) for anito-cel, the industry is closely watching the upcoming PDUFA date of December 23, 2026. The Gilead Sciences Acquisition of Arcellx ensures that Gilead’s industry-leading manufacturing infrastructure is fully prepared to scale production upon approval.
Anito-cel’s unique D-Domain binder technology allows for a high density of CAR expression on the cell surface, which researchers believe contributes to the lack of delayed neurotoxicities a side effect that has plagued other treatments in this class.
Last Modified:
